Diabetes: CGM Goes Mainstream
Executive Summary
Getting a breakthrough medical device from the drawing board into mainstream use is the primary goal of every manufacturer, but a variety of factors influences how quickly a device reaches that goal - if at all. Right now, that process is playing out in the diabetes market, where continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps.